GSK advances in Hepatitis B cure with FDA’s fast track for bepirovirsen
In a significant development for the treatment of chronic hepatitis B (CHB), GSK plc (LSE/NYSE: GSK) has announced that the US Food and Drug Administration ... Read More
Wave Life Sciences, GSK partner on oligonucleotide-based gene therapies
Wave Life Sciences and GSK have forged a partnership to discover and develop oligonucleotide therapeutics, focusing on new genetic targets, for respiratory diseases. The discovery ... Read More
Aligos Therapeutics stops development of CHB drug candidate ALG-010133
Aligos Therapeutics has stopped further development of ALG-010133, its STOPS drug candidate, in chronic hepatitis B (CHB) owing to futility. The California-based clinical stage biopharma ... Read More
Antios Therapeutics begins phase 1 trial for ATI-2173, a chronic hepatitis B candidate
US biopharma company Antios Therapeutics has initiated its first-in-human phase 1 clinical trial for ATI-2173, a liver-targeted, orally-administered, small molecule against hepatitis B. The phase ... Read More